Anti-Influenza A, HA (Clone HA-2B9) – Biotin
Anti-Influenza A, HA (Clone HA-2B9) – Biotin
Product No.: H294
- -
- -
Product No.H294 Clone HA-2B9 Target HA ⋅ Influenza A Formats AvailableView All Product Type Recombinant Monoclonal Antibody Alternate Names Hemagglutinin, H1 Isotype Rabbit IgG κ Applications ELISA |
- -
- -
Antibody DetailsProduct DetailsReactive Species viral Expression Host HEK-293 Cells Immunogen Influenza A HA protein (Product No.: F618) Product Concentration 0.5 mg/ml Formulation This Biotinylated antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative. State of Matter Liquid Storage and Handling This biotinylated antibody is stable when stored at 2-8°C. Do not freeze. Regulatory Status Research Use Only Country of Origin USA Shipping 2 – 8° C Wet Ice Applications and Recommended Usage? Quality Tested by Leinco ELISA Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionDescriptionSpecificity HA-1E10 activity is directed against the hemagglutinin head of Influenza A virus. Background Influenza A causes large numbers of infections and deaths annually, necessitating broad research into vaccines and therapeutics1. Influenza A viruses are classified into subtypes based on the antigenicity of hemagglutinin (HA), the predominant glycoprotein found on the viral surface. There are 18 HA subtypes, which are subdivided into two groups: Group 1 (H1, H2, H5, H6, H8, H9, H11, H12, H13, H16, H17 and H18) and Group 2 (H3, H4, H7, H10, H14 and H15). HA has a receptor binding function that promotes viral entry by engaging sialylated glycan receptors on host cells and enabling host membrane fusion. HA is constantly evolving to escape herd immunity and this can result in pandemics. HA is a homotrimer consisting of two domains: a globular, antigenically variable head and a more conserved, membrane-proximal stem1,2. Neutralizing antibodies targeting the head domain are typically restricted to within subtype, while antibodies targeting the stem can act more broadly across subtypes2. Although most anti-HA antibodies are strain-specific, antibodies with broad neutralizing activity against multiple strains or subtypes have been found1. These broadly neutralizing antibodies are of research interest because they may enable the development of a universal influenza vaccine and/or monoclonal antibody therapy1,3. Characterization of HA-peptide antibody led to the identification of the commonly used HA-tag, a linear epitope of nine amino acids used for protein purification and labeling1. This epitope is not clinically useful because it is inaccessible in the native HA conformation. Antigen Distribution Hemagglutinin is present on the influenza viral surface. NCBI Gene Bank ID UniProt.org Research Area Infectious Disease References & Citations1 Wu NC, Wilson IA. Cold Spring Harb Perspect Med. 10(8):a038778. 2020. 2 Bangaru S, Lang S, Schotsaert M, et al. Cell. 177(5):1136-1152.e18. 2019. 3 Yang F, Yan S, Zhu L, et al. Antiviral Res. 208:105462. 2022. Technical ProtocolsCertificate of Analysis |
Formats Available
- -
- -
Prod No. | Description |
---|---|
H293 | |
H294 |
Products are for research use only. Not for use in diagnostic or therapeutic procedures.